FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010028239> ?p ?o ?g. }

• W2010028239 abstract "Abstract Background After several exploratory and confirmatory clinical trials, the intralesional administration of human recombinant epidermal growth factor (hrEGF) has been approved for the treatment of advanced diabetic foot ulcers (DFU). The aim of this work was to evaluate the effectiveness and safety of this procedure in medical practice. Methods A prospective, post-marketing active pharmacosurveillance was conducted in 41 hospitals and 19 primary care polyclinics. Patients with DFU received hrEGF, 25 or 75 μg, intralesionally 3 times per week until complete granulation of the ulcer or 8 weeks maximum, adjuvant to standard wound care. Outcomes measured were complete granulation, amputations, and adverse events (AE) during treatment; complete lesion re-epithelization and relapses in follow-up (median: 1.2; maximum 4.2 years). Results The study included 1788 patients with 1835 DFU (81% Wagner’s grades 3 or 4; 43% ischemic) treated from May 2007 to April 2010. Complete granulation was observed in 76% of the ulcers in 5 weeks (median). Ulcer non-ischemic etiology (OR: 3.6; 95% CI: 2.8-4.7) and age (1.02; 1.01-1.03, for each younger year) were the main variables with influence on this outcome. During treatment, 220 (12%) amputations (171 major) were required in 214 patients, mostly in ischemic or Wagner’s grade 3 to 5 ulcers. Re-epithelization was documented in 61% of the 1659 followed-up cases; 5% relapsed per year. AE (4171) were reported in 47% of the subjects. Mild or moderate local pain and burning sensation, shivering and chills, were 87% of the events. Serious events, not related to treatment, occurred in 1.7% of the patients. Conclusions The favorable benefit/risk balance, confirms the beneficial clinical profile of intralesional hrEGF in the treatment of DFUs." @default.
• W2010028239 created "2016-06-24" @default.
• W2010028239 creator A5004339231 @default.
• W2010028239 creator A5026195581 @default.
• W2010028239 creator A5028513622 @default.
• W2010028239 creator A5029528798 @default.
• W2010028239 creator A5032570636 @default.
• W2010028239 creator A5067036145 @default.
• W2010028239 creator A5068073560 @default.
• W2010028239 creator A5089488220 @default.
• W2010028239 date "2013-09-03" @default.
• W2010028239 modified "2023-10-06" @default.
• W2010028239 title "Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers" @default.
• W2010028239 cites W1941500241 @default.
• W2010028239 cites W1965676751 @default.
• W2010028239 cites W1965840806 @default.
• W2010028239 cites W1971266017 @default.
• W2010028239 cites W1974792145 @default.
• W2010028239 cites W1988691104 @default.
• W2010028239 cites W1991974656 @default.
• W2010028239 cites W1998976412 @default.
• W2010028239 cites W2005145996 @default.
• W2010028239 cites W2020812459 @default.
• W2010028239 cites W2028839182 @default.
• W2010028239 cites W2052038646 @default.
• W2010028239 cites W2053426008 @default.
• W2010028239 cites W2066219225 @default.
• W2010028239 cites W2071589323 @default.
• W2010028239 cites W2101705397 @default.
• W2010028239 cites W2104195235 @default.
• W2010028239 cites W2105962012 @default.
• W2010028239 cites W2107191818 @default.
• W2010028239 cites W2112706810 @default.
• W2010028239 cites W2119371546 @default.
• W2010028239 cites W2127757314 @default.
• W2010028239 cites W2128631083 @default.
• W2010028239 cites W2131226296 @default.
• W2010028239 cites W2135418362 @default.
• W2010028239 cites W2137173748 @default.
• W2010028239 cites W2148532477 @default.
• W2010028239 cites W2158883606 @default.
• W2010028239 cites W2165923869 @default.
• W2010028239 cites W2167011758 @default.
• W2010028239 cites W2167102581 @default.
• W2010028239 cites W2167520363 @default.
• W2010028239 cites W2170938576 @default.
• W2010028239 doi "https://doi.org/10.1186/2050-6511-14-44" @default.
• W2010028239 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3844572" @default.
• W2010028239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24004460" @default.
• W2010028239 hasPublicationYear "2013" @default.
• W2010028239 type Work @default.
• W2010028239 sameAs 2010028239 @default.
• W2010028239 citedByCount "21" @default.
• W2010028239 countsByYear W20100282392014 @default.
• W2010028239 countsByYear W20100282392015 @default.
• W2010028239 countsByYear W20100282392016 @default.
• W2010028239 countsByYear W20100282392017 @default.
• W2010028239 countsByYear W20100282392018 @default.
• W2010028239 countsByYear W20100282392019 @default.
• W2010028239 countsByYear W20100282392022 @default.
• W2010028239 countsByYear W20100282392023 @default.
• W2010028239 crossrefType "journal-article" @default.
• W2010028239 hasAuthorship W2010028239A5004339231 @default.
• W2010028239 hasAuthorship W2010028239A5026195581 @default.
• W2010028239 hasAuthorship W2010028239A5028513622 @default.
• W2010028239 hasAuthorship W2010028239A5029528798 @default.
• W2010028239 hasAuthorship W2010028239A5032570636 @default.
• W2010028239 hasAuthorship W2010028239A5067036145 @default.
• W2010028239 hasAuthorship W2010028239A5068073560 @default.
• W2010028239 hasAuthorship W2010028239A5089488220 @default.
• W2010028239 hasBestOaLocation W20100282391 @default.
• W2010028239 hasConcept C126322002 @default.
• W2010028239 hasConcept C134018914 @default.
• W2010028239 hasConcept C141071460 @default.
• W2010028239 hasConcept C188816634 @default.
• W2010028239 hasConcept C197934379 @default.
• W2010028239 hasConcept C2776055305 @default.
• W2010028239 hasConcept C2777858829 @default.
• W2010028239 hasConcept C2778144972 @default.
• W2010028239 hasConcept C2778594517 @default.
• W2010028239 hasConcept C2779384505 @default.
• W2010028239 hasConcept C2780269544 @default.
• W2010028239 hasConcept C535046627 @default.
• W2010028239 hasConcept C555293320 @default.
• W2010028239 hasConcept C71924100 @default.
• W2010028239 hasConceptScore W2010028239C126322002 @default.
• W2010028239 hasConceptScore W2010028239C134018914 @default.
• W2010028239 hasConceptScore W2010028239C141071460 @default.
• W2010028239 hasConceptScore W2010028239C188816634 @default.
• W2010028239 hasConceptScore W2010028239C197934379 @default.
• W2010028239 hasConceptScore W2010028239C2776055305 @default.
• W2010028239 hasConceptScore W2010028239C2777858829 @default.
• W2010028239 hasConceptScore W2010028239C2778144972 @default.
• W2010028239 hasConceptScore W2010028239C2778594517 @default.
• W2010028239 hasConceptScore W2010028239C2779384505 @default.
• W2010028239 hasConceptScore W2010028239C2780269544 @default.
• W2010028239 hasConceptScore W2010028239C535046627 @default.
• W2010028239 hasConceptScore W2010028239C555293320 @default.
• W2010028239 hasConceptScore W2010028239C71924100 @default.
• W2010028239 hasIssue "1" @default.

• next